Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14060094 | 0.88 | FFAR1 (0.39) | CES2CES1CA1CA2HDAC3 | |
| SCHEMBL12348299 | 0.87 | HSD17B10 (0.36) | CA1CA2HDAC3HDAC1HDAC7 | |
| SCHEMBL22606341 | 0.78 | CES2 (0.42) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL2949849 | 0.78 | MAOA (0.45) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL566487 | 0.77 | CES2 (0.46) | CES2CES1CA1CA2HDAC3 | |
| SCHEMBL771387 | 0.77 | LMNA (0.50) | CA1CA2MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL3558306 | 0.76 | MAOA (0.47) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL409541 | 0.75 | HDAC1 (0.54) | CES2CES1CA1CA2HDAC1 | |
| SCHEMBL4619841 | 0.75 | PLAU (0.54) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL5900818 | 0.75 | PRMT5 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-17 | — | — | US | disclosed |
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20250092033-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Avistone Biotechnology Co., Ltd. (CN) | 2025-03-20 | — | — | US | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3526202-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| EP-4458818-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Avistone Biotechnology Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| WO-2005044797-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | MERCK SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| EP-1409489-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003000694-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | OXTR, PRLHR, PGF | CES2 4721/4885CES1 4379/4885CA1 4729/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885CA1 354/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | CES2 3601/4885CES1 2599/4885CA1 3375/4885 |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | CES2 2932/4885CES1 943/4885CA1 4289/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885CA1 354/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885CA1 354/4885 |
| US-20250092033-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | CYP19A1, WEE1, WEE2 | CES2 2674/4885CES1 1380/4885CA1 1793/4885 |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CES2 1040/4885CES1 1785/4885CA1 828/4885 |
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | APP, APBA1, PRNP | CES2 4767/4885CES1 4447/4885CA1 2581/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CES2 1040/4885CES1 1785/4885CA1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.